The FDA has approved ledipasvir/sofosbuvir (Harvoni), a combination anti-viral drug for the treatment of the hepatitis C virus, according to a Medscape report.
Harvoni is the first combination drug for HCV treatment. It is also the first HCV treatment that does not require the use of interferon and ribavirin.
Sovaldi, the previously approved sofosbuvir portion of the combination drug, is one of the most expensive drugs in the United States. Harvoni is expected to cost even more, according to the report.
More articles on gastroenterology:
CMS to cover stool DNA test Cologuard
UPMC GI scope infection research could alter national guidelines
How to boost efficiency without sacrificing quality in GI
Harvoni is the first combination drug for HCV treatment. It is also the first HCV treatment that does not require the use of interferon and ribavirin.
Sovaldi, the previously approved sofosbuvir portion of the combination drug, is one of the most expensive drugs in the United States. Harvoni is expected to cost even more, according to the report.
More articles on gastroenterology:
CMS to cover stool DNA test Cologuard
UPMC GI scope infection research could alter national guidelines
How to boost efficiency without sacrificing quality in GI